Therapeutic advances for glioblastoma multiforme: Current status and future prospects Review

Robins, HI, Chang, S, Butowski, N et al. (2007). Therapeutic advances for glioblastoma multiforme: Current status and future prospects . Current Oncology Reports, 9(1), 66-70. 10.1007/BF02951428

cited authors

  • Robins, HI; Chang, S; Butowski, N; Mehta, M

abstract

  • Glioblastoma multiforme (GBM) is the most common central nervous system malignancy. It is rapidly progressive with rare opportunity for cure. After three-decades of laboratory and clinical research;: a newly evolved chemoradiotherpy approach using the alkylating agent temozolomide during and after radiotherapy has resulted in the first significant impact on this disease. Here we, discuss the basis for this positive interaction as well as potential mechanisms of resistance to it. Additionally, in the context of current and planned research, we explore approaches to take advantage of this combination and the use of targeted therapies to exploit cell signaling alterations found in GBM. We anticipate that a multimodality approach directed at tumor-specific biology will result in more meaningful advancements in the treatment of this fatal disease. Copyright © 2007 by Current Medicine Group LLC.

authors

publication date

  • January 1, 2007

published in

Digital Object Identifier (DOI)

start page

  • 66

end page

  • 70

volume

  • 9

issue

  • 1